Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)

• Status: Completed
• Trial end date: 2006-02-26
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rizatriptan

Criteria

Inclusion Criteria:

• Female patient at least 18 years old

• Patient has menses approximately monthly

• Patient has at least a 5 month history of migraine and at least a 6 month history of menstrual migraine

Exclusion Criteria:

• Pregnant and/or nursing

• Cardiovascular disease

• Uncontrolled hypertension